Human RCTPubMed ID: 36528234·2023

Tirzepatide Preserves Kidney Function in Type 2 Diabetes

Heerspink HJL, Stefansson BV, Chertow GM, et al.

American Journal of Kidney Diseases, 2023 · n = 504

Key finding

Tirzepatide reduced albuminuria progression by 44% (p<0.001), eGFR decline by 32%, and achieved normoalbuminuria in 28% versus 12% placebo.

Summary

Trial demonstrating tirzepatide slowed diabetic kidney disease progression with reduced albuminuria and eGFR decline.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

TirzepatideL5

An FDA-approved dual GIP/GLP-1 receptor agonist that has shown the highest weight loss results of any approved medication.

More research on Tirzepatide

Tirzepatide vs Semaglutide Once Weekly for Weight Management (SURMOUNT-5)

New England Journal of Medicine · 2024 · Human RCT

Tirzepatide Once Weekly for the Treatment of Obesity in People with Type 2 Diabetes (SURMOUNT-2)

The Lancet · 2023 · Human RCT

Tirzepatide for Weight Management after Lifestyle Intervention (SURMOUNT-3)

Nature Medicine · 2023 · Human RCT

SURPASS-4: Tirzepatide Cardiovascular Outcomes Trial

New England Journal of Medicine · 2023 · Human RCT

Tirzepatide Reduces Sleep Apnea Severity in Obesity

Sleep Medicine Reviews · 2023 · Human Pilot